

August 27, 2026

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

Sub: Update on subscription of stake in Neuome Technologies Private Limited

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”)

Dear Sir/ Madam,

With reference to the captioned subject and in continuation to our earlier intimation dated July 24, 2026, regarding the approval accorded by the Board of Dr. Lal Ventures Private Limited, Wholly Owned Subsidiary of the Company, for the subscription of 30% stake in Neuome Technologies Private Limited (“Neuome”). We wish to inform you that Dr. Lal Ventures Private Limited has completed the said subscription on August 27, 2026 as per the terms and conditions of the Agreement.

Pursuant to completion of said subscription, Neuome has now become associate of the Company.

The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 as amended from time to time, have already been duly intimated in the earlier intimation dated July 24, 2026.

We request you to please take the same on record.

Thanking You,
Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Vinay Gujral
Company Secretary & Compliance Officer